ChromaDex names Jeffrey Himmel CEO

Tuesday, January 24, 2012 08:39 AM

ChromaDex, based in Irvine, Calif., has named Jeffrey Himmel its new CEO. Previous CEO Frank Jaksch will assume the position of chief scientific officer and remain on the ChromaDex board of directors.

Himmel also has agreed to invest $1 million in ChromaDex.

Himmel previously has held positions at Rothschild and Jeffrey Martin, an over-the-counter pharmaceutical company founded by his father, Martin Himmel. He also is the former chairman of The Himmel Group and currently serves as a member of the board of directors of The Consumer Healthcare Products Association.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs